{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T15:35:34Z","timestamp":1790523334984,"version":"4.1.0"},"reference-count":129,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,12,5]],"date-time":"2018-12-05T00:00:00Z","timestamp":1543968000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1038\/s41401-018-0185-5","type":"journal-article","created":{"date-parts":[[2018,12,5]],"date-time":"2018-12-05T02:26:48Z","timestamp":1543976808000},"page":"571-582","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Human pharmacology of positive GABA-A subtype-selective receptor modulators for the treatment of anxiety"],"prefix":"10.1038","volume":"40","author":[{"given":"Xia","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joop","family":"van Gerven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,5]]},"reference":[{"key":"185_CR1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders, fifth edition: DSM-5\u00ae.","author":"American Psychiatric Association.","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fifth edition: DSM-5\u00ae. Arlington, VA: American Psychiatric Association; 2013."},{"issue":"5","key":"185_CR2","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1177\/0269881114525674","volume":"28","author":"DS Baldwin","year":"2014","unstructured":"Baldwin DS, Anderson IM, Nutt DJ, Allgulander C, Bandelow B, den Boer JA, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol. 2014;28:403\u201339.","journal-title":"J Psychopharmacol"},{"issue":"Suppl. 2","key":"185_CR3","first-page":"10","volume":"68","author":"RC Kessler","year":"2007","unstructured":"Kessler RC. The global burden of anxiety and mood disorders: putting the European Study of the Epidemiology of Mental Disorders (ESEMeD) findings into perspective. J Clin Psychiatry. 2007;68(Suppl. 2):10\u201319.","journal-title":"J Clin Psychiatry"},{"key":"185_CR4","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.euroneuro.2011.07.018","volume":"21","author":"HU Wittchen","year":"2011","unstructured":"Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, J\u00f6nsson B, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21:655\u201379.","journal-title":"Eur Neuropsychopharmacol"},{"key":"185_CR5","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1001\/archgenpsychiatry.2010.180","volume":"68","author":"RC Kessler","year":"2011","unstructured":"Kessler RC, Ormel J, Petukhova M, McLaughlin KA, Green JG, Russo LJ, et al. Development of lifetime comorbidity in the World Health Organization world mental health surveys. Arch Gen Psychiatry. 2011;68:90\u2013100.","journal-title":"Arch Gen Psychiatry"},{"key":"185_CR6","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1192\/bjp.bp.107.039107","volume":"192","author":"J Ormel","year":"2008","unstructured":"Ormel J, Petukhova M, Chatterji S, Aguilar-Gaxiola S, Alonso J, Angermeyer MC, et al. Disability and treatment of specific mental and physical disorders across the world. Br J Psychiatry. 2008;192:368\u201375.","journal-title":"Br J Psychiatry"},{"key":"185_CR7","doi-asserted-by":"publisher","unstructured":"Guo X, Meng Z, Huang G, Fan J, Zhou W, Ling W, et al. Meta-analysis of the prevalence of anxiety disorders in mainland China from 2000 to 2015. Sci Rep. 2016;6:28033. https:\/\/doi.org\/10.1038\/srep28033 .","DOI":"10.1038\/srep28033"},{"key":"185_CR8","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/nrn3621","volume":"14","author":"BJ Casey","year":"2013","unstructured":"Casey BJ, Craddock N, Cuthbert BN, Hyman SE, Lee FS, Ressler KJ. DSM-5 and RDoC: progress in psychiatry research? Nat Rev Neurosci. 2013;14:810\u20134.","journal-title":"Nat Rev Neurosci"},{"issue":"5","key":"185_CR9","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1017\/neu.2017.38","volume":"30","author":"Kiran Kumar Katakam","year":"2018","unstructured":"Katakam KK, Sethi NJ, Jakobsen JC, Gluud C. Great boast, small roast on effects of selective serotonin reuptake inhibitors: response to a critique of our systematic review. Acta Neuropsychiatr. 2018;30:251\u2013265.","journal-title":"Acta Neuropsychiatrica"},{"key":"185_CR10","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/sj.mp.4001852","volume":"11","author":"A Bystritsky","year":"2006","unstructured":"Bystritsky A. Treatment-resistant anxiety disorders. Mol Psychiatry. 2006;11:805\u201314.","journal-title":"Mol Psychiatry"},{"key":"185_CR11","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1017\/S1461145705006358","volume":"10","author":"DS Baldwin","year":"2007","unstructured":"Baldwin DS, Montgomery SA, Nil R, Lader M. Discontinuation symptoms in depression and anxiety disorders. Int J Neuropsychopharmacol. 2007;10:73\u201384.","journal-title":"Int J Neuropsychopharmacol"},{"key":"185_CR12","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1038\/nn.4101","volume":"18","author":"GG Calhoon","year":"2015","unstructured":"Calhoon GG, Tye KM. Resolving the neural circuits of anxiety. Nat Neurosci. 2015;18:1394\u2013404.","journal-title":"Nat Neurosci"},{"key":"185_CR13","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3389\/fnbeh.2014.00112","volume":"8","author":"A Adhikari","year":"2014","unstructured":"Adhikari A. Distributed circuits underlying anxiety. Front Behav Neurosci. 2014;8:112. https:\/\/doi.org\/10.3389\/fnbeh.2014.00112 .","journal-title":"Front Behav Neurosci"},{"key":"185_CR14","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S1053-8119(03)00078-8","volume":"19","author":"TD Wager","year":"2003","unstructured":"Wager TD, Phan KL, Liberzon I, Taylor SF. Valence, gender, and lateralization of functional brain anatomy in emotion: a meta-analysis of findings from neuroimaging. Neuroimage. 2003;19:513\u201331.","journal-title":"Neuroimage"},{"key":"185_CR15","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1006\/nimg.2002.1087","volume":"16","author":"KL Phan","year":"2002","unstructured":"Phan KL, Wager T, Taylor SF, Liberzon I. Functional neuroanatomy of emotion: a meta-analysis of emotion activation studies in PET and fMRI. Neuroimage. 2002;16:331\u201348.","journal-title":"Neuroimage"},{"key":"185_CR16","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1093\/scan\/nsq017","volume":"6","author":"JM Carlson","year":"2011","unstructured":"Carlson JM, Greenberg T, Rubin D, Mujica-Parodi LR. Feeling anxious: anticipatory amygdalo-insular response predicts the feeling of anxious anticipation. Soc Cogn Affect Neurosci. 2011;6:74\u201381.","journal-title":"Soc Cogn Affect Neurosci"},{"key":"185_CR17","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1176\/appi.ajp.2007.07030504","volume":"164","author":"A Etkin","year":"2007","unstructured":"Etkin A, Wager TD. Functional neuroimaging of anxiety: a metaanalysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. Am J Psychiatry. 2007;164:1476\u201388.","journal-title":"Am J Psychiatry"},{"key":"185_CR18","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.neuroimage.2005.07.007","volume":"29","author":"T Straube","year":"2006","unstructured":"Straube T, Glauer M, Dilger S, Mentzel HJ, Miltner WH. Effects of cognitive\u2013behavioral therapy on brain activation in specific phobia. Neuroimage. 2006;29:125\u201335.","journal-title":"Neuroimage"},{"key":"185_CR19","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/7854_2009_5","volume-title":"Behavioral Neurobiology of Anxiety and Its Treatment","author":"Amit Etkin","year":"2009","unstructured":"Etkin A. Functional neuroanatomy of anxiety: a neural circuit perspective. In: Stein MB, Steckler T, editors. Behavioral neurobiology of anxiety and its treatment. Berlin: Springer Verlag; 2009. p. 251\u201377."},{"key":"185_CR20","unstructured":"Davis M. Neural circuitry of anxiety and stress disorders. In: Davis KL, Charney D, Coyle JT, Nemeroff C, editors. Neuropsychopharmacology: the fifth generation of progress. Philadelphia: Lippincott, Williams, & Wilkins; 2002. p. 729\u201343."},{"key":"185_CR21","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0166-2236(97)01125-9","volume":"20","author":"A Pitkanen","year":"1997","unstructured":"Pitkanen A, Savander V, LeDoux JE. Organization of intraamygdaloid circuitries in the rat: an emerging framework for understanding functions of the amygdala. Trends Neurosci. 1997;20:517\u201323.","journal-title":"Trends Neurosci"},{"key":"185_CR22","doi-asserted-by":"publisher","first-page":"10575","DOI":"10.1523\/JNEUROSCI.19-23-10575.1999","volume":"19","author":"S Royer","year":"1999","unstructured":"Royer S, Martina M, Pare D. An inhibitory interface gates impulse traffic between the input and output stations of the amygdala. J Neurosci. 1999;19:10575\u201383.","journal-title":"J Neurosci"},{"key":"185_CR23","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1111\/j.1460-9568.1998.00299.x","volume":"10","author":"AL Jongen-Relo","year":"1998","unstructured":"Jongen-Relo AL, Amaral DG. Evidence for a GABAergic projection from the central nucleus of the amygdala to the brainstem of the macaque monkey: a combined retrograde tracing and in situ hybridization study. Eur J Neurosci. 1998;10:2924\u201333.","journal-title":"Eur J Neurosci"},{"key":"185_CR24","unstructured":"Forster GL, Novick AM, Scholl JL, Watt MJ. The role of the amygdala in anxiety disorders. In: Ferry B, editor. The amygdala: a discrete multitasking manager. Rijeka: InTech; 2012. p. 61\u2013102."},{"issue":"2","key":"185_CR25","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.neuron.2009.12.002","volume":"65","author":"Avishek Adhikari","year":"2010","unstructured":"Adhikari A, Topiwala MA, Gordon JA. Synchronized activity between the ventral hippocampus and the medial prefrontal cortex during anxiety. Neuron. 2010;65:257\u201369.","journal-title":"Neuron"},{"issue":"4","key":"185_CR26","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.neuron.2013.06.016","volume":"79","author":"Ada\u00a0C. Felix-Ortiz","year":"2013","unstructured":"Felix-Ortiz AC, Beyeler A, Seo C, Leppla CA, Wildes CP, Tye KM. BLA to vHPC inputs modulate anxiety-related behaviors. Neuron. 2013;79:658\u201364.","journal-title":"Neuron"},{"key":"185_CR27","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.neuroimage.2008.03.059","volume":"42","author":"H Kober","year":"2008","unstructured":"Kober H, Barret LF, Joseph J, Bliss-Moreau E, Lindquist K, Wager TD. Functional grouping and cortical-subcortical interactions in emotion: a meta-analysis of neuroimaging studies. Neuroimage. 2008;42:998\u20131031.","journal-title":"Neuroimage"},{"key":"185_CR28","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1037\/a0026517","volume":"12","author":"AB Satpute","year":"2012","unstructured":"Satpute AB, Mumford JA, Naliboff BD, Poldrack RA. Human anterior and posterior hippocampus respond distinctly to state and trait anxiety. Emotion. 2012;12:58\u201368.","journal-title":"Emotion"},{"key":"185_CR29","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.neuron.2009.05.026","volume":"62","author":"I Ehrlich","year":"2009","unstructured":"Ehrlich I, Humeau Y, Grenier F, Ciocchi S, Herry C, Luthi A. Amygdala inhibitory circuits and the control of fear memory. Neuron. 2009;62:757\u201371.","journal-title":"Neuron"},{"key":"185_CR30","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1038\/npp.2010.53","volume":"35","author":"SR Makkar","year":"2010","unstructured":"Makkar SR, Zhang SQ, Cranney J. Behavioral and neural analysis of GABA in the acquisition, consolidation, reconsolidation, and extinction of fear memory. Neuropsychopharmacology. 2010;35:1625\u201352.","journal-title":"Neuropsychopharmacology"},{"key":"185_CR31","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1152\/physrev.00037.2009","volume":"90","author":"HC Pape","year":"2010","unstructured":"Pape HC, Pare D. Plastic synaptic networks of the amygdala for the acquisition, expression, and extinction of conditioned fear. Physiol Rev. 2010;90:419\u201363.","journal-title":"Physiol Rev"},{"key":"185_CR32","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.neuroscience.2013.03.001","volume":"240","author":"J Courtin","year":"2013","unstructured":"Courtin J, Bienvenu TC, Einarsson EO, Herry C. Medial prefrontal cortex neuronal circuits in fear behavior. Neuroscience. 2013;240:219\u201342.","journal-title":"Neuroscience"},{"key":"185_CR33","doi-asserted-by":"publisher","first-page":"3508","DOI":"10.2174\/138161208786848784","volume":"14","author":"K Domschke","year":"2008","unstructured":"Domschke K, Zwanzger P. GABAergic and endocannabinoid dysfunction in anxiety\u2014future therapeutic targets? Curr Pharm Des. 2008;14:3508\u201317.","journal-title":"Curr Pharm Des"},{"key":"185_CR34","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.tins.2012.11.003","volume":"36","author":"A Holmes","year":"2013","unstructured":"Holmes A, Singewald N. Individual differences in recovery from traumatic fear. Trends Neurosci. 2013;36:23\u201331.","journal-title":"Trends Neurosci"},{"key":"185_CR35","doi-asserted-by":"publisher","first-page":"13112","DOI":"10.1523\/JNEUROSCI.1998-13.2013","volume":"33","author":"NM Holmes","year":"2013","unstructured":"Holmes NM, Parkes SL, Killcross AS, Westbrook RF. The basolateral amygdala is critical for learning about neutral stimuli in the presence of danger, and the perirhinal cortex is critical in the absence of danger. J Neurosci. 2013;33:13112\u201325.","journal-title":"J Neurosci"},{"key":"185_CR36","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/0091-3057(95)00153-N","volume":"52","author":"SK Sanders","year":"1995","unstructured":"Sanders SK, Shekhar A. Regulation of anxiety by GABAA receptors in the rat amygdala. Pharmacol Biochem Behav. 1995;52:701\u20136.","journal-title":"Pharmacol Biochem Behav"},{"key":"185_CR37","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.brainres.2009.02.042","volume":"1267","author":"CA Barbalho","year":"2009","unstructured":"Barbalho CA, Nunes-de-Souza RL, Canto-de-Souza A. Similar anxiolytic-like effects following intra-amygdala infusions of benzodiazepine receptor agonist and antagonist: evidence for the release of an endogenous benzodiazepine inverse agonist in mice exposed to elevated plus-maze test. Brain Res. 2009;1267:65\u201376.","journal-title":"Brain Res"},{"key":"185_CR38","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/0091-3057(95)00153-N","volume":"52","author":"SK Sanders","year":"1995","unstructured":"Sanders SK, Shekhar A. Regulation of anxiety by GABAA receptors in the rat amygdala. Pharmacol Biochem Behav. 1995;52:701\u20136.","journal-title":"Pharmacol Biochem Behav"},{"key":"185_CR39","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1177\/0269881110389092","volume":"26","author":"CM Del-Ben","year":"2012","unstructured":"Del-Ben CM, Ferreira CA, Sanchez TA, Alves-Neto WC, Guapo VG, de Araujo DB, et al. Effects of diazepam on BOLD activation during the processing of aversive faces. J Psychopharmacol. 2012;26:443\u201351.","journal-title":"J Psychopharmacol"},{"key":"185_CR40","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1001\/archpsyc.62.3.282","volume":"62","author":"MP Paulus","year":"2005","unstructured":"Paulus MP, Feinstein JS, Castillo G, Simmons AN, Stein MB. Dosedependent decrease of activation in bilateral amygdala and insula by lorazepam during emotion processing. Arch Gen Psychiatry. 2005;62:282\u20138.","journal-title":"Arch Gen Psychiatry"},{"key":"185_CR41","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1001\/archpsyc.1990.01810220033004","volume":"47","author":"DJ Nutt","year":"1990","unstructured":"Nutt DJ, Glue P, Lawson C, Wilson S. Flumazenil provocation of panic attacks. Evidence for altered benzodiazepine receptor sensitivity in panic disorder. Arch Gen Psychiatry. 1990;47:917\u201325.","journal-title":"Arch Gen Psychiatry"},{"key":"185_CR42","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S0006-3223(98)00295-9","volume":"45","author":"A Strohle","year":"1999","unstructured":"Strohle A, Kellner M, Holsboer F, Wiedemann K. Behavioral, neuroendocrine, and cardiovascular response to flumazenil: no evidence for an altered benzodiazepine receptor sensitivity in panic disorder. Biol Psychiatry. 1999;45:321\u20136.","journal-title":"Biol Psychiatry"},{"key":"185_CR43","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3413\/Nukmed-0647-14-03","volume":"53","author":"S Nikolaus","year":"2014","unstructured":"Nikolaus S, Hautzel H, M\u00fcller HW. Focus on GABA(A) receptor function. A comparative analysis of in vivo imaging studies in neuropsychiatric disorders. Nuklearmedizin. 2014;53:227\u201337.","journal-title":"Nuklearmedizin"},{"key":"185_CR44","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1001\/archpsyc.64.2.193","volume":"64","author":"G Hasler","year":"2007","unstructured":"Hasler G, van der Veen JW, Tumonis T, Meyers N, Shen J, Drevets WC. Reduced prefrontal glutamate\/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry. 2007;64:193\u2013200.","journal-title":"Arch Gen Psychiatry"},{"key":"185_CR45","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1002\/da.20262","volume":"24","author":"AV Kalueff","year":"2007","unstructured":"Kalueff AV, Nutt DJ. Role of GABA in anxiety and depression. Depress Anxiety. 2007;24:495\u2013517.","journal-title":"Depress Anxiety"},{"key":"185_CR46","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/mp.2010.120","volume":"16","author":"B Luscher","year":"2011","unstructured":"Luscher B, Shen Q, Sahir N. The GABAergic deficit hypothesis of major depressive disorder. Mol Psychiatry. 2011;16:383\u2013406.","journal-title":"Mol Psychiatry"},{"key":"185_CR47","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.neuropharm.2011.08.040","volume":"62","author":"H M\u00f6hler","year":"2012","unstructured":"M\u00f6hler H. The GABA system in anxiety and depression and its therapeutic potential. Neuropharmacology. 2012;62:42\u201353.","journal-title":"Neuropharmacology"},{"key":"185_CR48","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1176\/appi.ajp.157.7.1120","volume":"157","author":"JD Bremner","year":"2000","unstructured":"Bremner JD, Innis RB, Southwick SM, Staib L, Zoghbi S, Charney DS. Decreased benzodiazepine receptor binding in prefrontal cortex in combat-related post-traumatic stress disorder. Am J Psychiatry. 2000;157:1120\u20136.","journal-title":"Am J Psychiatry"},{"key":"185_CR49","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1001\/archpsyc.55.8.715","volume":"55","author":"AL Malizia","year":"1998","unstructured":"Malizia AL, Cunningham VJ, Bell CJ, Liddle PF, Jones T, Nutt DJ. Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. Arch Gen Psychiatry. 1998;55:715\u201320.","journal-title":"Arch Gen Psychiatry"},{"key":"185_CR50","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1001\/archpsyc.65.10.1166","volume":"65","author":"G Hasler","year":"2008","unstructured":"Hasler G, Nugent AC, Carlson PJ, Carson RE, Geraci M, Drevets WC. Altered cerebral gamma-aminobutyric acid type A-benzodiazepine receptor binding in panic disorder determined by [11C]flumazenil positron emission tomography. Arch Gen Psychiatry. 2008;65:1166\u201375.","journal-title":"Arch Gen Psychiatry"},{"key":"185_CR51","doi-asserted-by":"crossref","first-page":"133","DOI":"10.64719\/pb.4169","volume":"37","author":"CB Nemeroff","year":"2003","unstructured":"Nemeroff CB. The role of GABA in the pathophysiology and treatment of anxiety disorders. Psychopharmacol Bull. 2003;37:133\u201346.","journal-title":"Psychopharmacol Bull"},{"issue":"Suppl 1","key":"185_CR52","first-page":"11","volume":"65","author":"DJ Nutt","year":"2004","unstructured":"Nutt DJ, Malizia AL. Structural and functional brain changes in posttraumatic stress disorder. J Clin Psychiatry. 2004;65(Suppl 1):11\u20137.","journal-title":"J Clin Psychiatry"},{"key":"185_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.apha.2014.10.008","volume":"72","author":"H M\u00f6hler","year":"2015","unstructured":"M\u00f6hler H. The legacy of the benzodiazepine receptor: from flumazenil to enhancing cognition in Down syndrome and social interaction in autism. Adv Pharmacol. 2015;72:1\u201336.","journal-title":"Adv Pharmacol"},{"key":"185_CR54","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1046\/j.1440-1681.1999.03151.x","volume":"26","author":"M Chebib","year":"1999","unstructured":"Chebib M, Johnston GA. The \u2018ABC\u2019 of GABA receptors: a brief review. Clin Exp Pharmacol Physiol. 1999;26:937\u201340.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"185_CR55","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/nrn2370","volume":"9","author":"TC Jacob","year":"2008","unstructured":"Jacob TC, Moss SJ, Jurd R. GABA(A) receptor trafficking and its role in the dynamic modulation of neuronal inhibition. Nat Rev Neurosci. 2008;9:331\u201343.","journal-title":"Nat Rev Neurosci"},{"key":"185_CR56","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/87425","volume":"4","author":"J Horenstein","year":"2001","unstructured":"Horenstein J, Wagner DA, Czajkowski C, Akabas MH. Protein mobility and GABA-induced conformational changes in GABA(A) receptor pore-lining M2 segment. Nat Neurosci. 2001;4:477\u201385.","journal-title":"Nat Neurosci"},{"key":"185_CR57","doi-asserted-by":"publisher","first-page":"241","DOI":"10.2174\/156802611794863562","volume":"11","author":"E Sigel","year":"2011","unstructured":"Sigel E, Luscher BP. A closer look at the high affinity benzodiazepine binding site on GABAA receptors. Curr Top Med Chem. 2011;11:241\u20136.","journal-title":"Curr Top Med Chem"},{"key":"185_CR58","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/S0021-9258(18)45961-3","volume":"267","author":"HA Wieland","year":"1992","unstructured":"Wieland HA, L\u00fcddens H, Seeburg PH. A single histidine in GABAA receptors is essential for benzodiazepine agonist binding. J Biol Chem. 1992;267:1426\u20139.","journal-title":"J Biol Chem"},{"key":"185_CR59","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/molbev\/msl188","volume":"24","author":"SY Tsang","year":"2007","unstructured":"Tsang SY, Ng SK, Xu Z, Xue H. The evolution of GABAA receptor-like genes. Mol Biol Evol. 2007;24:599\u2013610.","journal-title":"Mol Biol Evol"},{"key":"185_CR60","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/75761","volume":"3","author":"RM McKernan","year":"2000","unstructured":"McKernan RM, Rosahl TW, Reynolds DS, Sur C, Wafford KA, Atack JR, et al. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABAA receptor \u03b11 subtype. Nat Neurosci. 2000;3:587\u201392.","journal-title":"Nat Neurosci"},{"key":"185_CR61","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.tips.2018.04.003","volume":"39","author":"E Engin","year":"2018","unstructured":"Engin E, Benham RS, Rudolph U. An emerging circuit pharmacology of GABA(A) receptors. Trends Pharmacol Sci. 2018;39:710\u201332.","journal-title":"Trends Pharmacol Sci"},{"key":"185_CR62","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1073\/pnas.0405621102","volume":"102","author":"JK Rowlett","year":"2005","unstructured":"Rowlett JK, Platt DM, Lelas S, Atack JR, Dawson GR. Different GABAA receptor subtypes mediate the anxiolytic, abuse-related, and motor effects of benzodiazepine-like drugs in primates. Proc Natl Acad Sci U S A. 2005;102:915\u201320.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"185_CR63","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/44579","volume":"401","author":"U Rudolph","year":"1999","unstructured":"Rudolph U, Crestani F, Benke D, Br\u00fcnig I, Benson JA, Fritschy JM, et al. Benzodiazepine actions mediated by specific g-aminobutyric acid A receptor subtypes. Nature. 1999;401:796\u2013800.","journal-title":"Nature"},{"key":"185_CR64","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nature06493","volume":"451","author":"J Knabl","year":"2008","unstructured":"Knabl J, Witschi R, H\u00f6sl K, Reinold H, Zeilhofer UB, Ahmadi S, et al. Reversal of pathological pain through specific spinal GABAA receptor subtypes. Nature. 2008;451:330\u20134.","journal-title":"Nature"},{"key":"185_CR65","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.pain.2008.10.015","volume":"141","author":"J Knabl","year":"2009","unstructured":"Knabl J, Zeilhofer UB, Crestani F, Rudolph U, Zeilhofer HU. Genuine antihyperalgesia by systemic diazepam revealed by experiments in GABAA receptor pointmutated mice. Pain. 2009;141:233\u20138.","journal-title":"Pain"},{"key":"185_CR66","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1124\/jpet.108.144568","volume":"327","author":"G Munro","year":"2008","unstructured":"Munro G, Lopez-Garcia JA, Rivera-Arconada I, Erichsen HK, Nielsen E\u00d8, Larsen JS, et al. Comparison of the novel subtype-selective GABAA receptor-positive allosteric modulator NS11394 [30-[5-(1-hydroxy-1-methyl-ethyl)-benzoimidazol-1-yl]biphenyl-2-carbonitrile] with diazepam, zolpidem, bretazenil, and gaboxadol in rat models of inflammatory and neuropathic pain. J Pharmacol Exp Ther. 2008;327:969\u201381.","journal-title":"J Pharmacol Exp Ther"},{"key":"185_CR67","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.neuropharm.2006.04.018","volume":"51","author":"JR Atack","year":"2006","unstructured":"Atack JR, Bayley PJ, Seabrook GR, Wafford KA, McKernan RM, Dawson GR. L-655,708 enhances cognition in rats but is not proconvulsant at a dose selective for \u03b15-containing GABAA receptors. Neuropharmacology. 2006;51:1023\u20139.","journal-title":"Neuropharmacology"},{"key":"185_CR68","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s00213-008-1357-7","volume":"202","author":"TM Ballard","year":"2009","unstructured":"Ballard TM, Knoflach F, Prinssen E, Borroni E, Vivian JA, Basile J, et al. RO4938581, a novel cognitive enhancer acting at GABAA \u03b15 subunit-containing receptors. Psychopharmacology (Berl). 2009;202:207\u201323.","journal-title":"Psychopharmacology (Berl)"},{"key":"185_CR69","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1021\/jm020582q","volume":"46","author":"MS Chambers","year":"2003","unstructured":"Chambers MS, Atack JR, Broughton HB, Collinson N, Cook S, Dawson GR, et al. Identification of a novel, selective GABAA a5 receptor inverse agonist which enhances cognition. J Med Chem. 2003;46:2227\u201340.","journal-title":"J Med Chem"},{"key":"185_CR70","doi-asserted-by":"publisher","first-page":"3713","DOI":"10.1523\/JNEUROSCI.5024-05.2006","volume":"26","author":"VY Cheng","year":"2006","unstructured":"Cheng VY, Martin LJ, Elliott EM, Kim JH, Mount HTJ, Taverna FA, et al. a5GABAA receptors mediate the amnestic but not sedative-hypnotic effects of the general anesthetic etomidate. J Neurosci. 2006;26:3713\u201320.","journal-title":"J Neurosci"},{"key":"185_CR71","doi-asserted-by":"publisher","first-page":"5572","DOI":"10.1523\/JNEUROSCI.22-13-05572.2002","volume":"22","author":"N Collinson","year":"2002","unstructured":"Collinson N, Kuenzi FM, Jarolimek W, Maubach KA, Cothliff R, Sur C, et al. Enhanced learning and memory and altered GABAergic synaptic transmission in mice lacking the \u03b15 subunit of the GABAA receptor. J Neurosci. 2002;22:5572\u201380.","journal-title":"J Neurosci"},{"key":"185_CR72","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1124\/jpet.105.092320","volume":"316","author":"GR Dawson","year":"2006","unstructured":"Dawson GR, Maubach KA, Collinson N, Cobain M, Everitt BJ, MacLeod AM, et al. An inverse agonist selective for \u03b15 subunit-containing GABAA receptors enhances cognition. J Pharmacol Exp Ther. 2006;316:1335\u201345.","journal-title":"J Pharmacol Exp Ther"},{"key":"185_CR73","doi-asserted-by":"publisher","first-page":"3788","DOI":"10.1021\/jm701433b","volume":"51","author":"D Harris","year":"2008","unstructured":"Harris D, Clayton T, Cook J, Sahbaie P, Halliwell RF, Furtm\u00fcller R, et al. Selective influence on contextual memory: physiochemical properties associated with selectivity of benzodiazepine ligands at GABAA receptors containing the a5 subunit. J Med Chem. 2008;51:3788\u2013803.","journal-title":"J Med Chem"},{"key":"185_CR74","doi-asserted-by":"publisher","first-page":"4690","DOI":"10.1111\/bph.12779","volume":"171","author":"O Bukalo","year":"2014","unstructured":"Bukalo O, Pinard CR, Holmes A. Mechanisms to medicines: elucidating neural and molecular substrates of fear extinction to identify novel treatments for anxiety disorders. Br J Pharmacol. 2014;171:4690\u2013718.","journal-title":"Br J Pharmacol"},{"key":"185_CR75","doi-asserted-by":"publisher","first-page":"795","DOI":"10.2174\/1568026023393507","volume":"2","author":"W Sieghart","year":"2002","unstructured":"Sieghart W, Sperk G. Subunit composition, distribution and function of GABAA receptor subtypes. Curr Top Med Chem. 2002;2:795\u2013816.","journal-title":"Curr Top Med Chem"},{"key":"185_CR76","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1126\/science.290.5489.131","volume":"290","author":"K L\u00f6w","year":"2000","unstructured":"L\u00f6w K, Crestani F, Keist R, Benke D, Br\u00fcnig I, Benson JA, et al. Molecular and neuronal substrate for the selective attenuation of anxiety. Science. 2000;290:131\u20134.","journal-title":"Science"},{"key":"185_CR77","doi-asserted-by":"publisher","first-page":"17154","DOI":"10.1073\/pnas.0508752102","volume":"102","author":"BK Yee","year":"2005","unstructured":"Yee BK, Keist R, von Boehmer L, Studer R, Benke D, Hagenbuch N, et al. A schizophrenia-related sensorimotor deficit links a3-containing GABAA receptors to a dopamine hyperfunction. Proc Natl Acad Sci U S A. 2005;102:17154\u20139.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"185_CR78","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/sj.bjp.0706056","volume":"144","author":"JR Atack","year":"2005","unstructured":"Atack JR, Hutson PH, Collinson N, Marshall G, Bentley G, Moyes C, et al. Anxiogenic properties of an inverse agonist selective for a3 subunit-containing GABAA receptors. Br J Pharmacol. 2005;144:357\u201366.","journal-title":"Br J Pharmacol"},{"key":"185_CR79","doi-asserted-by":"publisher","first-page":"10682","DOI":"10.1523\/JNEUROSCI.1166-05.2005","volume":"25","author":"R Dias","year":"2005","unstructured":"Dias R, Sheppard WFA, Fradley RL, Garrett EM, Stanley JL, Tye SJ, et al. Evidence for a significant role ofa3-containing GABAA receptors in mediating the anxiolytic effects of benzodiazepines. J Neurosci. 2005;25:10682\u20138.","journal-title":"J Neurosci"},{"key":"185_CR80","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1038\/npp.2016.49","volume":"41","author":"LM Behlke","year":"2016","unstructured":"Behlke LM, Foster RA, Liu J, Benke D, Benham RS, Nathanson AJ, et al. A pharmacogenetic \u2018restriction-of-function\u2019 approach reveals evidence for anxiolytic-like actions mediated by \u03b15-containing GABAA receptors in mice. Neuropsychopharmacology. 2016;41:2492\u2013501.","journal-title":"Neuropsychopharmacology"},{"key":"185_CR81","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1152\/jn.00539.2013","volume":"113","author":"EP Christian","year":"2015","unstructured":"Christian EP, Snyder DH, Song W, Gurley DA, Smolka J, Maier DL, et al. EEG-\u03b2\/\u03b3 spectral power elevation in rat: a translatable biomarker elicited by GABA(A\u03b12\/3)-positive allosteric modulators at nonsedating anxiolytic doses. J Neurophysiol. 2015;113:116\u201331.","journal-title":"J Neurophysiol"},{"key":"185_CR82","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.bcp.2014.12.010","volume":"93","author":"AG Lucas de","year":"2015","unstructured":"de Lucas AG, Ahring PK, Larsen JS, Rivera-Arconada I, Lopez-Garcia JA, Mirza NR, et al. GABAA \u03b15 subunit-containing receptors do not contribute to reversal of inflammatory-induced spinal sensitization as indicated by the unique selectivity profile of the GABAA receptor allosteric modulator NS16085. Biochem Pharmacol. 2015;93:370\u20139.","journal-title":"Biochem Pharmacol"},{"key":"185_CR83","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1038\/nn.4102","volume":"18","author":"P Botta","year":"2015","unstructured":"Botta P, Demmou L, Kasugai Y, Markovic M, Xu C, Fadok JP, et al. Regulating anxiety with extrasynaptic inhibition. Nat Neurosci. 2015;18:1493\u20131500.","journal-title":"Nat Neurosci"},{"key":"185_CR84","first-page":"134523","volume":"2012","author":"X Chen","year":"2012","unstructured":"Chen X, de Haas S, de Kam M, van Gerven J. An overview of the CNS-pharmacodynamic profiles of nonselective and selective GABA agonists. Adv Pharmacol Sci. 2012;2012:134523.","journal-title":"Adv Pharmacol Sci"},{"key":"185_CR85","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/bs.apha.2014.10.001","volume":"72","author":"F Crestani","year":"2015","unstructured":"Crestani F, Rudolph U. Behavioral functions of GABAA receptor subtypes--the Zurich experience. Adv Pharmacol. 2015;72:37\u201351.","journal-title":"Adv Pharmacol"},{"key":"185_CR86","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/bs.apha.2014.10.002","volume":"72","author":"W Sieghart","year":"2015","unstructured":"Sieghart W. Allosteric modulation of GABAA receptors via multiple drug-binding sites. Adv Pharmacol. 2015;72:53\u201396.","journal-title":"Adv Pharmacol"},{"key":"185_CR87","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1038\/nn1578","volume":"8","author":"EJ Nestler","year":"2005","unstructured":"Nestler EJ. Is there a common molecular pathway for addiction? Nat Neurosci. 2005;8:1445\u20139.","journal-title":"Nat Neurosci"},{"key":"185_CR88","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.neubiorev.2005.04.016","volume":"30","author":"RC Pierce","year":"2006","unstructured":"Pierce RC, Kumaresan V. The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse? Neurosci Biobehav Rev. 2006;30:215\u201338.","journal-title":"Neurosci Biobehav Rev"},{"key":"185_CR89","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/nature08758","volume":"463","author":"KR Tan","year":"2010","unstructured":"Tan KR, Brown M, Labou\u00e8be G, Yvon C, Creton C, Fritschy JM, et al. Neural bases for addictive properties of benzodiazepines. Nature. 2010;463:769\u201374.","journal-title":"Nature"},{"key":"185_CR90","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1073\/pnas.0405621102","volume":"102","author":"JK Rowlett","year":"2005","unstructured":"Rowlett JK, Platt DM, Lelas S, Atack JR, Dawson GR. Different GABAA receptor subtypes mediate the anxiolytic, abuse-related, and motor effects of benzodiazepine-like drugs in primates. Proc Natl Aca Sci U S A. 2005;102:915\u201320.","journal-title":"Proc Natl Aca Sci U S A."},{"key":"185_CR91","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1037\/1064-1297.15.4.328","volume":"15","author":"JK Rowlett","year":"2007","unstructured":"Rowlett JK, Lelas S. Comparison of zolpidem and midazolam self-administration under progressive-ratio schedules: consumer demand and labor supply analyses. Exp Clin Psychopharmacol. 2007;15:328\u201337.","journal-title":"Exp Clin Psychopharmacol"},{"key":"185_CR92","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1046\/j.1365-2125.2002.t01-10-01714.x","volume":"55","author":"SJ Visser de","year":"2003","unstructured":"de Visser SJ, van der Post JP, de Waal PP, Cornet F, Cohen AF, van Gerven JM. Biomarkers for the effects of benzodiazepines in healthy volunteers. Br J Clin Pharmacol. 2003;55:39\u201350.","journal-title":"Br J Clin Pharmacol"},{"key":"185_CR93","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S1054-3589(08)57004-9","volume":"57","author":"JR Atack","year":"2009","unstructured":"Atack JR. Subtype-selective GABA(A) receptor modulation yields a novel pharmacological profile: the design and development of TPA023. Adv Pharmacol. 2009;57:137\u201385.","journal-title":"Adv Pharmacol"},{"key":"185_CR94","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1177\/0269881106072343","volume":"21","author":"SL Haas de","year":"2007","unstructured":"de Haas SL, de Visser SJ, van der Post JP, de Smet M, Schoemaker RC, Rijnbeek B, et al. Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA(A) alpha(2,3) subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers. J Psychopharmacol. 2007;21:374\u201383.","journal-title":"J Psychopharmacol"},{"key":"185_CR95","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1177\/0269881107082108","volume":"22","author":"SL Haas de","year":"2008","unstructured":"de Haas SL, de Visser SJ, van der Post JP, Schoemaker RC, van Dyck K, Murphy MG, et al. Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA(A) alpha2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers. J Psychopharmacol. 2008;22:24\u201332.","journal-title":"J Psychopharmacol"},{"key":"185_CR96","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1177\/0269881108092595","volume":"23","author":"SL Haas de","year":"2009","unstructured":"de Haas SL, Franson KL, Schmitt JA, Cohen AF, Fau JB, Dubruc C, et al. The pharmacokinetic and pharmacodynamic effects of SL65.1498, a GABA-A alpha2,3 selective agonist, in comparison with lorazepam in healthy volunteers. J Psychopharmacol. 2009;23:625\u201332.","journal-title":"J Psychopharmacol"},{"key":"185_CR97","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1177\/0269881109106898","volume":"24","author":"SL Haas de","year":"2010","unstructured":"de Haas SL, Schoemaker RC, van Gerven JM, Hoever P, Cohen AF, Dingemanse J. Pharmacokinetics, pharmacodynamics and the pharmacokinetic\/ pharmacodynamic relationship of zolpidem in healthy subjects. J Psychopharmacol. 2010;24:1619\u201329.","journal-title":"J Psychopharmacol"},{"key":"185_CR98","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/j.1365-2125.2001.01308.x","volume":"51","author":"SJ Visser De","year":"2001","unstructured":"De Visser SJ, Van der Post J, Pieters MSM, Cohen AF, Van Gerven JMA. Biomarkers for the effects of antipsychotic drugs in healthy volunteers. Br J Clin Pharmacol. 2001;51:119\u201332.","journal-title":"Br J Clin Pharmacol"},{"key":"185_CR99","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/j.1365-2125.2005.02342.x","volume":"59","author":"GJH Dumont","year":"2005","unstructured":"Dumont GJH, De Visser SJ, Cohen AF, Van Gerven JMA. Biomarkers for the effects of selective serotonin reuptake inhibitors (SSRIs) in healthy volunteers. Br J Clin Pharmacol. 2005;59:495\u2013510.","journal-title":"Br J Clin Pharmacol"},{"key":"185_CR100","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1177\/0269881106063271","volume":"20","author":"GJM Dumont","year":"2006","unstructured":"Dumont GJ, Verkes RJ. A review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunteers. J Psychopharmacol. 2006;20:176\u201387.","journal-title":"J Psychopharm"},{"key":"185_CR101","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1365-2125.2008.03329.x","volume":"67","author":"L Zuurman","year":"2009","unstructured":"Zuurman L, Ippel AE, Moin E, Van Gerven JMA. Biomarkers for the effects of cannabis and THC in healthy volunteers. Br J Clin Pharmacol. 2009;67:5\u201321.","journal-title":"Br J Clin Pharmacol"},{"key":"185_CR102","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/j.1365-2125.2010.03846.x","volume":"71","author":"RWM Zoethout","year":"2011","unstructured":"Zoethout RWM, Delgado WL, Ippel AE, Dahan A, van Gerven JMA. Functional biomarkers for the acute effects of alcohol on the central nervous system in healthy volunteers. Br J Clin Pharmacol. 2011;71:331\u201350.","journal-title":"Br J Clin Pharmacol"},{"key":"185_CR103","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ddtec.2016.07.004","volume":"20","author":"GJ Groeneveld","year":"2016","unstructured":"Groeneveld GJ, Hay JL, van Gerven JM. Measuring blood-brain barrier penetration using the NeuroCart, a CNS test battery. Drug Discov Today Technol. 2016;20:27\u201334.","journal-title":"Drug Discov Today Technol"},{"key":"185_CR104","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1177\/026988119901300102","volume":"13","author":"AL Steveninck van","year":"1999","unstructured":"van Steveninck AL, van Berckel BN, Schoemaker RC, Breimer DD, van Gerven JM, Cohen AF. The sensitivity of pharmacodynamic tests for the central nervous system effects of drugs on the effects of sleep deprivation. J Psychopharmacol. 1999;13:10\u20137.","journal-title":"J Psychopharmacol"},{"key":"185_CR105","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1517\/14728214.2015.1049996","volume":"20","author":"JW Murrough","year":"2015","unstructured":"Murrough JW, Yaqubi S, Sayed S, Charney DS. Emerging drugs for the treatment of anxiety. Expert Opin Emerg Drugs. 2015;20:393\u2013406.","journal-title":"Expert Opin Emerg Drugs"},{"key":"185_CR106","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3389\/fnins.2016.00539","volume":"10","author":"AJ Loonen","year":"2016","unstructured":"Loonen AJ, Ivanova SA. Circuits regulating pleasure and happiness: the evolution of the amygdalar-hippocampal-habenular connectivity in vertebrates. Front Neurosci. 2016;10:539\u201355.","journal-title":"Front Neurosci"},{"key":"185_CR107","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/nrd4075","volume":"12","author":"G Griebel","year":"2013","unstructured":"Griebel G, Holmes A. 50 years of hurdles and hope in anxiolytic drug discovery. Nat Rev Drug Discov. 2013;12:667\u201387.","journal-title":"Nat Rev Drug Discov"},{"key":"185_CR108","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.pharmthera.2012.12.002","volume":"138","author":"V Micale","year":"2013","unstructured":"Micale V, Di Marzo V, Sulcova A, Wotjak CT, Drago F. Endocannabinoid system and mood disorders: priming a target for new therapies. Pharmacol Ther. 2013;138:18\u201337.","journal-title":"Pharmacol Ther"},{"issue":"11","key":"185_CR109","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1517\/14728222.2011.628314","volume":"15","author":"Gang Wu","year":"2011","unstructured":"Wu G, Feder A, Wegener G, Bailey C, Saxena S, Charney D, et al. Central functions of neuropeptide Y in mood and anxiety disorders. Expert Opin Ther Targets. 2011;15:1317\u201331.","journal-title":"Expert Opinion on Therapeutic Targets"},{"issue":"8","key":"185_CR110","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1517\/13543784.2013.803066","volume":"22","author":"Joanna M Wiero\u0144ska","year":"2013","unstructured":"Wieronska JM, Pilc A. Glutamate-based anxiolytic ligands in clinical trials. Expert Opin Investig Drugs. 2013;22:1007\u201322.","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"185_CR111","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nbt.2083","volume":"30","author":"M Allison","year":"2012","unstructured":"Allison M. Reinventing clinical trials. Nat Biotechnol. 2012;30:41\u20139.","journal-title":"Nat Biotechnol"},{"key":"185_CR112","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.drudis.2011.12.020","volume":"17","author":"P Morgan","year":"2012","unstructured":"Morgan P, Van Der Graaf PH, Arrowsmith J, Feltner DE, Drummond KS, Wegner CD, et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving phase II survival. Drug Discov Today. 2012;17:419\u201324.","journal-title":"Drug Discov Today"},{"key":"185_CR113","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/j.1365-2125.2005.02342.x","volume":"59","author":"GJH Dumont","year":"2005","unstructured":"Dumont GJH, De Visser SJ, Cohen AF, Van Gerven JMA. Biomarkers for the effects of selective serotonin reuptake inhibitors (SSRIs) in healthy volunteers. Br J Clin Pharmacol. 2005;59:495\u2013510.\u00a0","journal-title":"Br J Clin Pharmacol"},{"key":"185_CR114","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1111\/bcp.12413","volume":"78","author":"X Chen","year":"2014","unstructured":"Chen X, Jacobs G, de Kam M, Jaeger J, Lappalainen J, Maruff P, et al. The central nervous system effects of the partial GABA-A\u03b12,3 -selective receptor modulator AZD7325 in comparison with lorazepam in healthy males. Br J Clin Pharmacol. 2014;78:1298\u2013314.","journal-title":"Br J Clin Pharmacol"},{"key":"185_CR115","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/JCP.0000000000000251","volume":"35","author":"X Chen","year":"2015","unstructured":"Chen X, Jacobs G, de Kam ML, Jaeger J, Lappalainen J, Maruff P, et al. AZD6280, a novel partial \u03b3-aminobutyric acid A receptor modulator, demonstrates a pharmacodynamically selective effect profile in healthy male volunteers. J Clin Psychopharmacol. 2015;35:22\u201333.","journal-title":"J Clin Psychopharmacol"},{"key":"185_CR116","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1177\/0269881115620435","volume":"30","author":"RG Zuiker","year":"2016","unstructured":"Zuiker RG, Chen X, \u00d8sterberg O, Mirza NR, Muglia P, de Kam M, et al. NS11821, a partial subtype-selective GABAA agonist, elicits selective effects on the central nervous system in randomized controlled trial with healthy subjects. J Psychopharmacol. 2016;30:253\u201362.","journal-title":"J Psychopharmacol"},{"key":"185_CR117","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.2147\/NDT.S45931","volume":"9","author":"J Bittencourt","year":"2013","unstructured":"Bittencourt J, Velasques B, Teixeira S, Basile LF, Salles JI, Nardi AE, et al. Saccadic eye movement applications for psychiatric disorders. Neuropsychiatr Dis Treat. 2013;9:1393\u2013409.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"185_CR118","doi-asserted-by":"publisher","first-page":"e86474","DOI":"10.1371\/journal.pone.0086474","volume":"9","author":"NT Chen","year":"2014","unstructured":"Chen NT, Clarke PJ, Watson TL, Macleod C, Guastella AJ. Biased saccadic responses to emotional stimuli in anxiety: an antisaccade study. PLoS ONE. 2014;9:e86474.","journal-title":"PLoS ONE"},{"key":"185_CR119","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/7854_2009_30","volume":"2","author":"JR Atack","year":"2010","unstructured":"Atack JR. GABAA receptor \u03b12\/\u03b13 subtype-selective modulators as potential nonsedating anxiolytics. Curr Top Behav Neurosci. 2010;2:331\u201360.","journal-title":"Curr Top Behav Neurosci"},{"key":"185_CR120","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.neuropharm.2010.10.020","volume":"60","author":"H Mohler","year":"2011","unstructured":"Mohler H. The rise of a new GABA pharmacology. Neuropharmacology. 2011;60:1042\u20139.","journal-title":"Neuropharmacology"},{"key":"185_CR121","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/cpdd.165","volume":"4","author":"ET Beek Te","year":"2015","unstructured":"Te Beek ET, Chen X, Jacobs GE, Nahon KJ, De Kam ML, Lappalainen J, et al. The effects of the nonselective benzodiazepine lorazepam and the \u03b12\/\u03b13 subunit\u2010selective GABAA receptor modulators AZD7325 and AZD6280 on plasma prolactin levels. Clin Pharmacol Drug Dev. 2015;4:49\u2013154.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"185_CR122","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1159\/000119437","volume":"23","author":"Z Zemishlany","year":"1990","unstructured":"Zemishlany Z, McQueeney R, Gabriel SM, Davidson M. Neuroendocrine and monoaminergic responses to acute administration of alprazolam in normal subjects. Neuropsychobiology. 1990;23:124\u20138.","journal-title":"Neuropsychobiology"},{"key":"185_CR123","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/0165-1781(94)90051-5","volume":"53","author":"S Sevy","year":"1994","unstructured":"Sevy S, Brown SL, Wetzler S, Kotler M, Molcho A, Plutchik R, et al. Effects of alprazolam on increases in hormonal and anxiety levels induced by meta-chlorophenylpiperazine. Psychiatry Res. 1994;53:219\u201329.","journal-title":"Psychiatry Res"},{"key":"185_CR124","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1177\/0269881109358200","volume":"24","author":"M Liem-Moolenaar","year":"2010","unstructured":"Liem-Moolenaar M, te Beek ET, de Kam ML, Franson KL, Kahn RS, Hijman R, et al. Central nervous system effects of haloperidol on THC in healthy male volunteers. J Psychopharmacol. 2010;24:1697\u2013708.","journal-title":"J Psychopharmacol"},{"key":"185_CR125","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00213-009-1516-5","volume":"205","author":"JPM Baas","year":"2009","unstructured":"Baas JPM, Mol N, Kenemans JL, Prinssen EP, Niklson I, Xia-Chen C, et al. Validating a human model for anxiety using startle potentiated by cue and context: the effects of alprazolam, pregabalin, and diphenhydramine. Psychopharmacology (Berl). 2009;205:73\u201384.","journal-title":"Psychopharmacology (Berl)"},{"key":"185_CR126","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/nrd3502","volume":"10","author":"U Rudolph","year":"2011","unstructured":"Rudolph U, Knoflach F. Beyond classical benzodiazepines: novel therapeutic potential of GABA(A) receptor subtypes. Nat Rev Drug Discov. 2011;10:685\u201397.","journal-title":"Nat Rev Drug Discov"},{"key":"185_CR127","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S0022-3565(24)29437-4","volume":"298","author":"G Griebel","year":"2001","unstructured":"Griebel G, Perrault G, Simiand J, Cohen C, Granger P, Decobert M, et al. SL651498: an anxioselective compound with functional selectivity for alpha2- and alpha3-containing gamma-aminobutyric acid (A) (GABA(A)) receptors. J Pharmacol Exp Ther. 2001;298:753\u201368.","journal-title":"J Pharmacol Exp Ther"},{"key":"185_CR128","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0014-2999(02)02191-X","volume":"451","author":"E Sanna","year":"2002","unstructured":"Sanna E, Busonero F, Talani G, Carta M, Massa F, Peis M, et al. Comparison of the effects of zaleplon, zolpidem, and triazolam at various GABA(A) receptor subtypes. Eur J Pharmacol. 2002;451:103\u201310.","journal-title":"Eur J Pharmacol"},{"key":"185_CR129","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/sj.bjp.0703717","volume":"131","author":"F Crestani","year":"2000","unstructured":"Crestani F, Martin JR, Mohler H, Rudolph U. Mechanism of action of the hypnotic zolpidem in vivo. Br J Pharmacol. 2000;131:1251\u20134.","journal-title":"Br J Pharmacol"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41401-018-0185-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41401-018-0185-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41401-018-0185-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T09:07:37Z","timestamp":1775293657000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-018-0185-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,5]]},"references-count":129,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["185"],"URL":"https:\/\/doi.org\/10.1038\/s41401-018-0185-5","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,5]]},"assertion":[{"value":"25 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}